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Advances in technology and transparency have greatly accelerated the ability of clinicians to 
remain current with regards to being informed and informing patients about the risk/benefit ratio 
when considering antidepressant medication. In spite of this, the current climate of 
pharmaceutical industry influence on medical practice does much to hinder informed consent 
processes. Recent findings of previously unknown and potentially dangerous adverse effects of 
the second- and third-generation classes of antidepressants underscore the importance of 
enhancing the practice of informed consent. After considering the concept of informed consent 
as it has evolved over time, the authors summarize some of the newer side effects associated 
with second- and third-generation antidepressants and then move on to describe impediments in 
the way of achieving adequate informed consent at the clinical encounter. Among these 
impediments, the authors discuss the impact of industry influence, cognitive bias in decision-
making, and time constraints. These obstacles and the notion that modern antidepressants are not 
as safe as once thought offer an opportunity to revisit the process of informed consent. A 
dynamic concept of informed consent is proposed with the acknowledgement that a mere listing 
of side effects or pro forma approach to informed consent is inadequate, and that a deep and 
ongoing conversation with patients will more likely result in patient empowerment and a 
strengthening of the therapeutic alliance. This process is analogized to an “n=1” approach where 
patients’ idiosyncratic responses to second- and third-generation antidepressants can be used to 
update prior beliefs based on large-scale trials and allow patient and doctor to shoulder the 
burden of uncertainty together, thereby enhancing placebo and minimizing nocebo response and 
leading to more optimal treatment outcomes. 




 Over the last few decades, evidence-based approaches to the management of psychiatric 
disorders have incorporated the concept of concordance or shared decision-making between 
clinicians and patients (Appelbaum & Grisso, 1997; Deegan & Drake, 2006; Penston, 2007). As 
a result the paradigm has shifted from a paternalistic model, where the clinician makes decisions 
for patients, to a patient-choice model. However, the prevalence of academic-industry 
collaborations, the dramatic increase in industry-funded research,  the financial ties between 
prescribing providers, organized medicine, and the pharmaceutical industry, and the rise of 
psychopharmacology as the predominant intervention in psychiatry have complicated, and in 
some ways compromised, the informed consent process. For example, there is evidence of 
attempts by some pharmaceutical companies to influence vital information regarding efficacy 
and safety studies in high ranking medical journals through practices such as ghost writing and 
selective reporting of clinical trials and outcomes. In addition, there is documented variability in 
the reporting of harm-related results in publications of randomized controlled trials (Howland, 
2011; Pitrou, Boutron, Ahmed, & Ravaud, 2010; Spielmans & Parry, 2010). Despite these 
clearly unethical practices, the problem most often “is not venality or intentional deception…. 
The problem is that bias can so easily be introduced unintentionally” (Avorn & Choudhry, 2010, 
p. 2233). As a result, the published literature may not fully capture a balanced view of the 
risk/benefit ratio for commonly prescribed psychotropic medications such as antidepressants. 
 The fact that clinicians may be receiving imbalanced and perhaps inaccurate or biased 
information about the side effect profiles of newer antidepressants is particularly problematic in 
light of the rise in antidepressant use. A recent Center for Disease Control report announced that 
there has been a 400% increase in the use of antidepressants since 1988; currently over twenty-
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seven million people in the United States are taking antidepressants. In addition to being the 
standard treatment for depressive disorders, antidepressants are increasingly being prescribed for 
other conditions such as chronic daily headache, back pain, neuropathy, sleep-related conditions, 
fatigue, anxiety spectrum disorders (e.g., social anxiety disorder and panic disorder), adjustment 
disorders, eating disorders, fibromyalgia, and hot flashes.
 
This widening range of use may be 
driven in part by the longstanding perception that modern antidepressants are extremely safe. 
However, recent research has shed a more sobering light on the actual safety and tolerability 
profiles of second- and third-generation antidepressants. Policy makers, bioethicists, and health 
care professionals are thus in full agreement that providers need to “integrate information about 
medical risks of serotonergic antidepressants into their clinical decision-making, informed 
consent process, baseline assessment, and follow-up monitoring” (Looper, 2007: 7; see also 
Bahrick & Harris, 2008).  
Despite the concern that these data have generated, however, it seems that clinical 
practice has yet to adapt. A recent study demonstrated that in only 1.5% to 2% of clinical 
sessions did psychiatrists discuss the issue of adverse effects with their patients after initiating 
treatment with an antidepressant (Linden & Westram, 2011).  Moreover, informed consent is 
hardly mentioned in the American Psychiatric Association's clinical practice guidelines for the 
treatment of Major Depressive Disorder (American Psychiatric Association, 2010).  
 The recent discoveries of new and potentially dangerous adverse effects of 
antidepressants, along with the compromised state of informed consent practice, warrant a 
reappraisal of the informed consent process regarding these common medications. In this article, 
after considering the concept of informed consent as it has evolved over time, the authors review 
the adverse effects associated with second- and third-generation antidepressants and then move 
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on to discuss various impediments to the informed consent process, such as the influence of the 
pharmaceutical industry on the information available to prescribers and its quality, cognitive 
biases in decision making, and the widespread conceptualization of informed consent as a single 
action. The authors conclude by reframing informed consent as a dynamic rather than a pro 
forma process that involves approaching antidepressant prescription empirically and 
collaboratively, allowing doctor and patient to manage uncertainty together within the treatment 
alliance and leading to more optimal treatment outcomes.  
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Informed consent: A brief history and context 
As Beauchamp (2011) noted, although the term ‘informed consent’ emerged in the 1950s, 
serious discussion about the meaning of informed consent, particularly in terms of the patient’s 
or research participant’s perspective (i.e., his/her actual understanding of the information being 
disclosed), did not receive serious attention until the 1970s. The concept of informed consent as 
it applies to research was first formally defined by the Nuremberg Code in 1947 and continued to 
be updated over time by various organizations, including the World Medical Association in 
Helsinki in 2004 (http://ohsr.od.nih.gov/guidelines/helsinki.html). Over time the concept of 
informed consent in clinical practice evolved as well and came to signify “the disclosure of 
important information so that a patient may be able to assess the risks and benefits of the 
proposed treatments and understand the alternatives to the proposed treatment” (see e.g., 
Bursztajn, Feinbloom, Hamm, & Brodsky, 1990; Gutheil, Bursztajn, & Brodsky, 1984). 
Although there are different standards for disclosure, such as the professional practice 
standard, which focuses on the question of the customary practices of the profession, it is the 
reasonable patient standard that is used most frequently in the United States as the required 
threshold for disclosure. This standard, derived from the landmark Canterbury v. Spence federal 
court ruling, can be stated as following: “What would a reasonable patient want to know with 
respect to the proposed therapy and the dangers that may be inherently or potentially involved”
1
 
(464 F.2d 772, 1972). A risk is considered material when a reasonable person, in what the 
physician knows or should know to be the patient's position, would be likely to attach a 
significance to the risk or cluster of risks in deciding whether or not to forego the proposed 
                                                          
1
 Canterbury v. Spence, 464 F.2d 772, 1972. 





 (Cantebury v. Spence, 464; Foy v. Greenblott, 141 Cal. App. 3d. 1, 9, 1983; Mathis v. 
Morrissey, 11 Cal. App. 4th 332 [13 Cal. Rptr. 2d 819], 1992). In 2003, a review (Mazur) noted 
that the reasonable patient standard for informed consent was gaining currency not only in the 
United States but also internationally, in Canada, Great Britain, and Australia.  This trend has 
continued to date and given the globalization of clinical trials is likely to continue. Moreover, 
given the adoption and usage of a variety of “universal” human subject protection codes on the 
heels of the Nuremberg trials, the international influence of the reasonable patient standard for 
informed consent is likely to grow.   
Despite these major legal rulings, the emergence of an entire field of bioethics, and the 
proliferation of literature on the topic of informed consent, the practice of making sure that one 
obtains meaningful informed consent “has been slow to conform to abstract theory” 
(Beauchamp, 2011, p.517). Moreover, the concept of informed consent was developed when 
medical information was far more static and trust in biomedicine and regulatory bodies was 
taken for granted. The framers of informed consent practices could not have anticipated an 
information age in which advances in technology allow immediate and public access to emerging 
data regarding drug efficacy and side effects. Nor could they have anticipated the prevalence of 
collaborations between academic organizations and the pharmaceutical industry—collaborations 
that have raised real questions about how meaningful the informed consent process can be if 
practitioners are not privy to accurate and complete data on efficacy and risks of medications. 
                                                          
2
 Foy v. Greenblott, 141 Cal. App. 3d. 1, 9, 1983. 
3
 Mathis v. Morrissey, 11 Cal. App. 4th 332 [13 Cal. Rptr. 2d 819], 1992. 
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  In order to respect patient autonomy, the informed consent process must begin with 
physicians who have a clear understanding of the risks and benefits inherent in prescribing a 
medication as well as how various alternatives fare in comparison. In today's industry-dominated 
climate, marketing and publishing tactics utilized by drug companies make it difficult for the 
prescriber to be adequately informed. Indeed, the field of medicine has had to contend with some 
glaring examples of iatrogenic harm caused by the distortion of important information about a 
drug’s adverse effects. Merck’s blockbuster drug Vioxx (Rofecoxib), which nearly doubled the 
risk of myocardial infarction and stroke (Bresalier et al., 2005; Avorn & Choudhry, 2010), is 
perhaps the most well-known case. As a result of this and other high profile cases, providing 
genuine informed consent has become a critical public health issue for all medical subspecialties. 
We therefore proceed with a survey of some of the known adverse effects of the second- and 
third-generation antidepressants.  
 
 
DYNAMIC INFORMED CONSENT PROCESSES VITAL FOR TREATMENT WITH ANTIDEPRESSANTS 8 
 
  
Side effects and adverse events 
Post-market monitoring of second- and third-generation antidepressants has called into 
question the perception that they are mostly safe. Recent meta-analyses and reviews of safety 
and tolerability information of clinical trials provide the bulk of data underlying this concern (see 
Table 1: Summary of side effects and adverse events associated with second- and third-
generation antidepressants).  For example, in an updated meta-analysis, Gartlehner et al. (2011) 
found that 63% of patients reported at least one adverse event during the course of treatment and 
that discontinuation rates between selective serotonin reuptake inhibitors (SSRIs) and other 
second-generation antidepressants were generally similar. Of note is that due to the size and 
length of most trials, the authors conclude that comparative risk across drugs for serious adverse 
events other than sexual dysfunction (i.e., suicidality, cardiovascular events, hyponatremia, 
seizures, hepatotoxicity, and serotonin syndrome) could not be determined. Since such clinical 
trials cannot sufficiently capture the less common but more serious adverse events, the United 
States Food and Drug Administration (FDA) depends on post-market surveillance in order to 
detect and respond to these events (Wolfe, 2012). 
One serious adverse event that does appear in clinical trials is sexual side effects. 
Montejo-Gonzalez et al. (1997) found that over 50% of subjects taking an SSRI experienced 
some type of sexual dysfunction, with decreased libido and delayed orgasm being the most 
common. Clayton, Keller, and McGarvey (2006) note that even for patients who do not qualify 
for global sexual dysfunction, 96% of female patients and 98% of male patients taking SSRIs 
experience dysfunction in at least one sexual phase. Seidman (2006) noted that at least 25% of 
men taking SSRIs experience delayed ejaculation. This phenomenon is likely underreported, as 
the correlation between SSRIs and delayed ejaculation in men is not well-researched. 




Other SSRI side effects continue to be discovered.  Recent reports suggest that SSRIs 
increase the risk of upper gastrointestinal (GI) tract bleeding (Dalton, Sørenson, & Johansen, 
2006; de Abajo, Montero, Rodriguez, & Madurga, 2008; Loke, Trivedi, & Singh, 2007) and pose 
particular problems for the elderly, including increased risk for falls, bone fractures (Hermann 
2000; Richards et al., 2007), and hyponatremia (Movig, 2002), and a possible effect on 
intraocular pressure for those at risk for glaucoma (Costagliola, Parmeggiani, & Sebastiani, 
2004). Ziere et al. (2008) found that SSRI use more than doubles the risk of nonvertebral 
fracture, with the risk increasing in those taking an SSRI for more than six months. Weight gain 
associated with SSRI use (Fava, 2000) has led to concerns about increased diabetes risk with 
long-term use (Andersohn, Schade, Suisse, & Garbe, 2009). Haddad and Dursun (2008) also note 
the increased risk of serotonin toxicity and discontinuation syndrome in patients treated with 
SSRIs. Rarely, suicidality is also associated with antidepressant use (Reeves & Ladner, 2010), 
with some evidence of increased risk with SSRIs relative to tricyclic antidepressants (TCAs) 
(Fergusson et al., 2005; Gunnell, Saperia, & Ashby, 2005). 
In addition, studies have documented adverse neonatal outcomes in relation to maternal 
exposure to SSRIs and other newer serotonergic/noradrenergic antidepressants from the last 
trimester through delivery, including mild central nervous system, motor, respiratory, and GI 
signs and metabolic dysfunction (see Tuccori et al., 2009 for review) as well as cardiovascular 
defects (Diav-Citrin et al., 2008; Louik, Lin, Werler, Hernandex-Diaz, & Mitchell, 2007) and a 
risk of persistent pulmonary hypertension (Chambers et al., 2006).  
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Progress in the field of pharmacodynamics has led to increasing concerns about the 
complex relationships among serotonin, SSRIs, certain TCAs, prolactin, and tamoxifen, and how 
these inter-relationships affect both pharmacodynamics and cancer risk (Kelly et al., 
2010). Some antidepressants, especially SSRIs, are potent inhibitors of the cytochrome P450 
monooxygenase enzymatic system (a system that metabolizes antineoplastic as well as 
other agents). Thus, antidepressants may directly enhance tumor cell proliferation as suggested 
by the expanding biological and clinical research on cytochrome P450 enzymes and 
the deleterious effects of these enzymes on the metabolism and therapeutic efficacy of tamoxifen 
and other antineoplastic agents (Spina et al., 2008; Aubert et al., 2009).   In fact, researchers 
found an increased risk of death from breast cancer in 630 women taking paroxetine while 
receiving tamoxifen therapy (Kelly et al., 2010).  Moreover, women treated with tamoxifen who 
were also treated with a moderate to potent cytochrome P2D6 inhibitor (fluoxetine, paroxetine, 
or sertraline) were found to have an increased risk of a breast cancer recurrence compared to 
women taking no SSRI (Aubert et al., 2009), although it should be said that in another study 
researchers did not observe an elevated risk of breast cancer recurrence in women treated with 
antidepressant inhibitors of cytochrome P2D6 (Azoulay, Dell’Aniello, Huiart, Galbaud du Fort, 
& Suissa, 2011). 
 In sum, although the more recent findings regarding adverse events are preliminary, they 
raise significant questions about the safety and tolerability of second- and third-generation 
antidepressants and prompt a revisiting of the informed consent process for this class of drugs. 
Drugs once considered to be safe and tolerable, with sexual dysfunction and GI discomfort 
thought to be their primary adverse effects, are now suspected to carry serious risks such as 
gastrointestinal bleeding and an increased risk of fractures. This problematic situation is further 
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complicated by marketing practices distorted by financial conflicts of interest and places a heavy 
burden of responsibility on clinicians to avoid pitfalls and manage uncertainties within the 
process of informed consent so that patient autonomy will not be compromised. 
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Communicating the emerging data on side effects: Toward a more genuine informed 
consent process 
Industry plays a dominating role in psychopharmacological education (Brodkey, 2005; 
Gagnon & Lexchin, 2008), and there is increasing documentation that the evidence base gets 
distorted as a result of these partnerships (Friedman & Richter, 2004). It is noteworthy that the 
financing for educational/promotional activities of pharmaceutical companies are derived from 
their marketing and administrative budgets (Brodkey, 2005). It is therefore important for 
prescribers to be mindful of pharmaceutical marketing strategies and to actively seek information 
from independent sources (e.g., the Cochrane Central Register of Controlled Trials and 
MedWatch, the FDA website for updated reporting of safety information and adverse events) 
rather than relying on updates regarding the risks and benefits of any given medication from an 
industry-sponsored source (Applbaum 2009; Shaughnessy, Slawson, & Bennett, 1994; 
Spielmans & Parry, 2010).  
Semantic decision-making biases often combine with marketing strategies to form 
another potential pitfall on the way to genuine informed consent (Bursztajn et al., 1991; 
Bursztajn, Chanowitz, Gutheil, & Hamm, 1992). For example, warnings and contraindications 
buried in the “adverse events” section of the labeling of a pharmaceutical product are not likely 
to be remembered as well as the indications and benefits that are prominently promoted. 
Moreover, the consequences of automated thinking (Hamm, 2009b) and the “irrational 
persistence in belief” (Hamm, 2009a)
 
may be reinforced by delays in disclosing adverse effects 
of medications.  Many clinicians have internalized the belief that second- or third-generation 
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antidepressants are always the treatment of choice. Once such automatic prescribing habits set in 
they become difficult to dislodge.  Additionally, industry promotion can subtly—but 
powerfully—frame the questions clinicians ask. For example, the “newer is better” bias 
encourages questions such as “Which among this new class of drugs is better than the others?” 
rather than "How are these new drugs any better than older drugs or alternative treatments?" 
In order to facilitate collaborative decision-making, it is important for clinicians not only 
to review independent sources of information for emerging safety and efficacy data, but also to 
initiate conversations with their patients about these new data. It is helpful to communicate to 
patients that it is indeed difficult to make sense of all of the information they hear and read about 
regarding their psychotropic medications (e.g., in direct-to-consumer advertising campaigns, 
news stories, etc.). Evidence suggests that prescribing physicians vary in their beliefs about what 
constitutes an adequate level of knowledge disseminated to patients about relative benefits and 
harms of treatments (Larkin, Clifton, & de Visser, 2009; Laugharne, Davies, Arcelus, & 
Bouman, 2004). Instead of adopting a “don’t ask, don’t tell” policy, it is recommended that 
clinicians specifically invite patients to voice any and all concerns about a medication’s side 
effects or lack of effectiveness (Cosgrove & Bursztajn 2007). The clinician who is proactive and 
takes care to inform patients during the course of treatment about newly emerging data is more 
likely to enhance a trusting relationship and therapeutic alliance than one who avoids difficult 
dialogues.  
Emerging evidence on antidepressant side effects and efficacy also invite a shift in 
attitude regarding the prescription of antidepressants from standardized to empirical. There is an 
argument to be made that updated data on the variable efficacy of antidepressants in treating 
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mild to moderate depression (Fournier et al., 2010) have transformed American Psychiatric 
Association guidelines recommending standard treatment into an investigative process for each 
individual patient. With increasing applicability of the reasonable person standard as outlined 
earlier, this shift would necessitate the tactful updating of patients who previously believed that 
their treatment was standard with the information that their treatment is empirical and in effect, a 
one-person experiment. 
In this spirit, and rather than being bound solely by statistics culled from studies 
involving large numbers of subjects, we suggest that clinicians adopt an “n=1” attitude to the 
weighing of risks and benefits with patients. Average rates taken from studies will of course 
inform our prior probabilities of adverse events and initial conversations with patients, but the 
informed consent process is best conceptualized as a collaborative journey where both benefits 
and side effects are continually updated for each individual patient. This is particularly important 
in light of data suggesting that the presence of mental illness can complicate a patient’s response 
to medications and may result in intolerance or even the experience of rare side effects (Davies, 
Jackson, Ramsay, & Ghahramani, 2003), and moreover that idiosyncratic reactions to SSRIs 
abound, with outcomes from any single medication trial often being unpredictable (Berndt, 
Bhattacharjya, Mishol, Arcelus, & Lasky, 2002).  
These waters of uncertainty suggest a larger role for the informed consent process itself 
as a conduit for treatment. By initiating a conversation with patients that includes not just 
frequent psychoeducation and provisions for close monitoring, but also an exploration of 
patients’ expectations and the meaning of medications as it relates to their identity and suffering, 
physicians may be able both to enhance placebo and minimize nocebo effects that are typical of 
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pharmacologic treatment of depression (Fournier et al., 2010). A dynamic approach to informed 
consent can do much to distinguish pharmacology from mere pill-dispensing (Gopal, 
Pirakitikuir, & Bursztajn, 2005) and presents an opportunity to manage the ambiguity 








Clinicians today practice in a time-limited, pharmaceutical-industry dominated climate in 
which reductive biological models are heavily promoted. Such models reinforce an acontextual 
view of patients’ problems and a disease- rather than patient-centered model of care.  As a result, 
“diagnosis by checklist” (Andreasen, 2007) becomes a primary source of automatic prescribing 
(Cosgrove & Bursztajn, 2007). Thus, genuine informed consent requires, first and foremost, that 
mental health professionals adopt a mindful approach to psychiatric taxonomy and be aware not 
only of the uses, but also the limitations of and alternatives to psychopharmacological 
interventions. Respecting patient autonomy requires that clinicians be aware of the marketing 
practices and biases that may distort their appraisal of the relative risks and benefits of 
medications such as antidepressants, and moreover that they consider the ways in which people 
can be manipulated by social constructions of normalcy and health in an industry-dominated 
climate (see e.g., Ells, 2003). This increasingly complex network of considerations presents 
distinct challenges for clinicians, but dynamic informed consent processes offer a way to 
acknowledge the uncertainty associated with antidepressants while simultaneously empowering 
patients in their recovery from illness. 
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Table 1: Summary of side effects and adverse events associated with second- and third-
generation antidepressants 
First Author  Year of 
Publication 



















Clayton 2006 Cross-sectional 
observational 
study 
95.6% of women 
and 97.9% of 
men who do not 





dysfunction in at 
least one phase. 
Sexual  
Dalton 2006 Review Evidence for a 
causal role of 
Gastrointestinal 
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SSRIs in upper 
GI bleeding 
events. 
De Abajo 2008 Review Evidence for 
increased risk of 
upper GI 
bleeding with 






Loke 2007 Systematic 
review 
Use of SSRIs 
alone and with 
NSAIDs 
increases the risk 
of upper GI 
bleeding.  
Gastrointestinal 
Herrmann 2000 Review Potential adverse 









Richards 2007 Prospective 
cohort study 
Associated with 
increased risk for 




















Costagliola 2004 Review Relationship 
between SSRI 








Ramasubbu 2004 Systematic 
review 

























Fava 2000 Review Use of SSRIs as 




Andersohn 2009 Case-control Risk of diabetes 
mellitus 
increased with 














Reeves 2010 Review Evidence 
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Gunnell 2005 Meta-analysis Some evidence 
for increased risk 
of self-harm and 
moderate risk of 
suicidal thoughts. 
 























Diav-Citrin 2008 Prospective 
cohort study 
Exposure to 









Louik 2007 Case-control 
study 
Some SSRIs may 
increase risk of 
certain 
cardiovascular 
defects in infants 





Chambers 2006 Case-control 
study 
Association 
between use of 
SSRIs in late 
pregnancy and 







Kelly 2010 Population-based 
cohort study 
Concomitant use 
of paroxetine and 
tamoxifen 
association with 











Spina 2008 Review Second-
generation 
antidepressants 







Aubert 2009 Retrospective 
cohort study 
Clinically 
significant 
interaction 
between 
tamoxifen and 
CYP2D6 
inhibitors, which 
includes some 
second-
generation 
antidepressants. 
Special 
populations: 
breast cancer 
patients 
 
